Maybe Dr. Kim himself---greatly admire him not only for how he is running this company but also for backing his belief in the science by putting his own money into buying company stock-he's admitted that 99% of his net worth is in INO stock
Sure I'm disappointed in the performance since Mr. Perrin took over--but this situation reminds me of April 2013 when all the "naysayers" were saying the FDA would never allow this trial to even start--I simply refuse to give up on this company---I challenge anyone to show me a biotech company that has the scientific advisory board that In Vivo has---I don't see any of them "abandoning ship"--and I'm sure if they didn't believe this would be successful they would have bailed out long ago-I will continue to "hold tight" as I believe this trial is ultimately going to be the start of a revolutionary treatment for patients who have had little or no hope before
The only thing "Sad" PAL is you--you continually ridicule this company from every conceivable angle and seem to take great pleasure doing so--you define the word narcisist to a tee-vent your stupid opinions somewhere else-
Sure I can--but I don't acknowledge useless "trolls" like you--and that's all you are--all you do all day is respond to any positive messages and ridicule the person doing it--as a result you don't deserve any response--and I won't lower myself to your level to do so
In Vivo has no control over when this trial starts--its up to each of the designated trauma centres/neurosurgeons in charge to decide if the trial entry criteria are met--I rather they take their time getting this started and get everything right
where did you come up with 25-40% number from???
1 40/40 African Green Monkey were up and moving after implantation of the scaffold
2 these monkeys have 98-99% of the genetic profile of humans
3 the "neuroplastisity" reponse in humans is far greater than in this species of monkey (as quoted by Dr. Slotkin on the NVIV scientific advisory board)
4 this trial only has to achieve "safety"-and since this polymer that composes the scaffold was approved and has been used in many applications already by the FDA--this won't be an issue
-I wouldn't bet against this trial AT ALL
and some of the best neurosurgeons in the US are involved in this--and I'm sure if they thought this was some kind of "crapshoot" they wouldn't even bother participating in it
nobody could care one iota for your stupid comments--you have been bashing this stock from day 1--so why are you back? just to antagonize we who believe in this company and their mission---go share your "expert opinion" on another board--but I'm sure you have been a pain in the #$%$ everywhere you've turned up
The biggest "joke" is you and your "ilk" PAL---take you're "shortie" act somewhere else!!!
I would bet if this is very successful on patients who meet the criteria for inclusion in this trial-then neurosurgeons will "throw caution to the wind" and start using it in patients who don't fit the typical criteria--because patients and their families will be clamoring for it-and who could blame them if the alternative is long term (if not permanent) disability
management said any "partnership" agreement would be 3-6 weeks after announcement of FDA approval--so anywhere between-July 18 to August 8
Points that are all well taken
--what do you think would be a "reasonable" pps if partnership vs complete takeover? I doubt MNKD would agree to a complete takeover--the technosphere technology will be a "cash cow" for the company for years---but if Mr. Mann agrees to a takeover this potential had better be factored into the final price
MNKD once traded at $20 pps without any FDA approval (then fell after the 2nd CRL letter)---why would it be in "low teens" after acceptance--nonsense-Mr. Mann would have to be "demented" to settle for such a "low ball" offer even if it was just a partnership
Are you kidding me?? MNKD was $20 pps prior to its second CRL letter and that was with no approval--why would Mr. Mann settle for "13-14" on a buyout??? I DON'T THINK SO!!
why is Barrons suggesting to "take profits" now?? just an attempt to scare Longs into getting rid of at least some of their shares so they can be bought up before the partnership/buyout announcement at a cheaper price? I thought Barrons would be above something like this?
"InVivo Therapeutics Holdings Corp. (NVIV) today announced that the role of Christopher McNulty has been expanded to include investor relations and corporate communications"
Hopefully this means more "transparency" and updates as to what is going on--something that has been greatly lacking since Mr. Perrin took over from Mr. Astrue-in fact I can't remember one time that Mr. Perrin directly addressed shareholders in a news release etc.
Clovis is $40 pps-although 1 year target is $80 pps---do you see anything else that is more affordable that has MNKD's potential? Thks
That will depend on if there are at least some positive results from one of these clinical trial sites---how can they make any kind of deal if there are no positive results-otherwise they are just selling an idea not a workable product